Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alnylam Pharmaceuticals reports robust 2022 performance and growth opportunities

Alnylam Pharmaceuticals had a strong financial performance in 2022, driven by the success of AMVUTTRA and advancements in ATTR amyloidosis treatments.
While facing challenges such as FDA requests and the need for self-sustainability, the company is poised for growth with projected revenues and pipeline opportunities.
Opportunities lie in market expansion, innovative pipeline programs, and upcoming regulatory milestones, positioning Alnylam for continued success in RNAi therapeutics.

Alnylam Pharmaceuticals posts robust Q1 growth despite FDA challenges

Alnylam Pharmaceuticals reported strong financial performance in Q1 2023, driven by the TTR franchise and key product sales growth. Despite challenges with the FDA's partial clinical hold, the company remains optimistic about pipeline development and addressing unmet patient needs with RNAi therapeutics.

Alnylam Pharmaceuticals excels in Q2, poised for growth and innovation

Alnylam Pharmaceuticals delivered strong financial results, positive clinical data, and strategic partnerships in Q2 2023, positioning itself for continued growth.
While facing challenges such as market competition and regulatory complexities, Alnylam remains focused on innovation, patient care, and commercial success.
The company's emphasis on R&D, market positioning, and leveraging its RNAi platform underscores its commitment to advancing therapies and driving value for stakeholders.

Alnylam Pharmaceuticals reports robust Q3 growth and eyes HELIOS-B opportunities

Alnylam Pharmaceuticals delivered strong financial results in Q3 2023, showcasing growth and innovation in its product portfolio and pipeline. Despite challenges, the company remains focused on long-term strategies and seizing opportunities in the evolving healthcare landscape.

Alnylam Pharmaceuticals excels in 2023, poised for market leadership

Alnylam Pharmaceuticals demonstrated strong financial performance in 2023, with notable achievements in commercial RNAi therapeutics and franchise growth. The company's strategic focus on innovation, study optimization, and market positioning bodes well for future success and market leadership in RNAi therapeutics.

Alnylam Pharmaceuticals reports robust Q1 performance and strategic readiness

Alnylam Pharmaceuticals showcased strong financial performance, strategic focus on patient needs, and readiness for upcoming milestones.
While facing challenges in meeting guidance and ensuring successful launches, the company is well-positioned for growth and innovation.
Opportunities lie in upcoming milestones, secondary endpoint focus, and future catalysts, driving potential value creation and differentiation.

Alnylam Pharmaceuticals excels in Q2 2024, poised for sustained growth

Alnylam Pharmaceuticals demonstrated strong financial performance and clinical advancements in Q2 2024, driven by key revenue growth drivers and pipeline progress.
While facing challenges such as rising expenses, the company's strategic strengths in franchise performance and margin improvement position it well for future opportunities.
With upcoming milestones and increased guidance, Alnylam is poised to capitalize on growth prospects and maintain its position as a leader in rare disease therapeutics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock?

Why Is Alnylam (ALNY) Down 7% Since Last Earnings Report?

Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.

Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus

Inovio Pharmaceuticals

Moderna

Vir Biotechnology

U.S. lawmakers' deal to find a vaccine for tackling the coronavirus stands to benefit the healthcare industry.

House Okays $8 Billion Funds to Combat COVID-19: 3 Winners

The World Health Organization increased its mortality estimate for the rapidly-spreading illness.

WHO Says Coronavirus Death Rate Is Higher Than Previously Thought

The two biotechs are expanding their existing collaboration with the goal of developing an antiviral treatment for the novel coronavirus.

Vir Biotechnology and Alnylam Join the Fight Against COVID-19

Alnylam Pharmaceuticals and Vir Biotechnology are teaming up to tackle forms of coronavirus, including Covid-19, the biotech companies said Wednesday. Shares of both jumped in early action.

Why These 2 Biotech Companies Are Pairing Up To Tackle Coronavirus

Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.

Alnylam's Givlaari Gets Approval in Europe for Rare Disease

Vir Biotechnology Inc (NASDAQ: VIR) is stepping up its COVID-19 fighting efforts and the quest has rewarded its shareholders.

Vir Biotech, Alnylam Stitch COVID-19 Therapy Partnership

Vir Biotechnology Inc. shares VIR, -8.96% rose 13% in premarket trade Wednesday, after the company said it is expanding its collaboration with Alnylam Pharmaceuticals Inc.

Vir Biotechnology and Alnylam Pharma to collaborate on RNAi Therapeutics to treat coronavirus

Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.

Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat

Shares of the genetic disease specialist were essentially flat in late afternoon trading.

Alnylam Beats Revenue Estimates, but Misses on Earnings

Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q4 2019 Results - Earnings Call Transcript

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q4 Earnings Expected to Decline

Alnylam Pharmaceuticals Beats Again, But The Bar Keeps Moving Higher

Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

All of the share price gains came after September -- and for good reason.

Why Alnylam Pharmaceuticals Rose 57.9% in 2019

Shares of Alnylam (ALNY) rise on significant pipeline progress.

Alnylam Stock Up More Than 61% YTD on Pipeline Progress

Global Blood Therapeutics

Novartis

Patients who inherit life-threatening blood disorders have some important new treatment options.

3 Rare Disease Drug Launches to Watch in 2020

With Positive Phase III Data From Lumasiran, Alnylam On Track For Another Approval

Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.

Alnylam's Kidney Disease Drug Succeeds in Late Stage Study

Dicerna Pharmaceuticals

Shares of Alnylam Pharmaceuticals tried to rally Tuesday after the biotech company's RNAi technology succeeded in a kidney disease. But Alnylam has some rivals waiting in the winds.

Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally Fails

Shares of Alnylam Pharmaceuticals Inc. ALNY, -1.52% are up 1% in morning trading on the news that lumasiran, its investigational rare disease therapy, met its primary endpoint in a Phase 3 trial.

Alnylam's shares rise on late-stage rare disease results

Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Alnylam (ALNY) Moves to Buy: Rationale Behind the Upgrade

Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals (ALNY)

Alnylam Continues To Deliver On RNAi Pipeline With Alternative Treatment Option For Rare Disease

News for Alnylam Pharmaceuticals Stock (ALNY)